Shares of DaVita Inc. (NYSE:DVA – Get Free Report) have been assigned an average recommendation of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $166.33.
A number of equities analysts have recently issued reports on the stock. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Barclays lifted their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th.
Get Our Latest Research Report on DVA
Institutional Investors Weigh In On DaVita
DaVita Trading Up 4.0 %
NYSE:DVA opened at $149.22 on Friday. DaVita has a 1 year low of $125.64 and a 1 year high of $179.60. The stock has a market cap of $11.94 billion, a P/E ratio of 13.89, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a 50-day simple moving average of $158.87 and a 200-day simple moving average of $157.62.
DaVita (NYSE:DVA – Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Can TikTok Stock Picks Really Make You Rich?
- The 3 Best Retail Stocks to Shop for in August
- The “Quality” Rotation: Back to Basics Investing
- Where to Find Earnings Call Transcripts
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.